PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition–related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status–dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser10 is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers. [Mol Cancer Ther 2007;6(12):3158–68]

[1]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[2]  J. Peters,et al.  The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint , 2003, The Journal of cell biology.

[3]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Ichihara,et al.  The RET proto‐oncogene: A molecular therapeutic target in thyroid cancer , 2005, Cancer science.

[5]  Paola Storici,et al.  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. , 2006, Journal of medicinal chemistry.

[6]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Chiao-Ying Lin,et al.  Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[8]  R. Margolis,et al.  Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. , 2001, Molecular biology of the cell.

[9]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[11]  Richard Bayliss,et al.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. , 2003, Molecular cell.

[12]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[13]  Chung F. Wong,et al.  Exploiting novel cell cycle targets in the development of anticancer agents. , 2005, Current cancer drug targets.

[14]  M. Santoro,et al.  Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line , 1995 .

[15]  Domenico Coppola,et al.  Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  H. Kawai,et al.  Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation , 2005, Oncogene.

[17]  Antonella Isacchi,et al.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.

[18]  E. Scanziani,et al.  Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre‐clinical trials , 2007, The Prostate.

[19]  R. Motzer,et al.  Sunitinib malate for the treatment of solid tumours: a review of current clinical data , 2006, Expert opinion on investigational drugs.

[20]  Michael H Atkins,et al.  Sunitinib maleate , 2006, Nature Reviews Drug Discovery.

[21]  Tong Tong,et al.  Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma , 2004, Clinical Cancer Research.

[22]  A. Balmain,et al.  Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. , 2005, Carcinogenesis.

[23]  P. Chieffi,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):928–935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1518 Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phe , 2004 .

[24]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[25]  H. Katayama,et al.  Mitotic kinase expression and colorectal cancer progression. , 1999, Journal of the National Cancer Institute.

[26]  G. Schwartz,et al.  Aurora Kinases: New Targets for Cancer Therapy , 2006, Clinical Cancer Research.

[27]  J. Harper,et al.  Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.

[28]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[29]  S. Nicosia,et al.  Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215* , 2004, Journal of Biological Chemistry.

[30]  C. Allis,et al.  Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases , 2002, Molecular and Cellular Biology.

[31]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[32]  Hui Yang,et al.  Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase , 2005, FEBS letters.

[33]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[34]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[35]  D. Ballinari,et al.  PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity , 2006, Clinical Cancer Research.

[36]  J. Verweij,et al.  Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? , 2006, European Journal of Cancer.

[37]  P. Dobrzanski,et al.  The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Loda,et al.  The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.

[39]  D. Bergstrom,et al.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.

[40]  C. Sawyers,et al.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.

[41]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[42]  L. Mariani,et al.  RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  H. Friess,et al.  Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  A. Strife,et al.  Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies , 2003, Leukemia.

[45]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[46]  A. Vulpetti,et al.  Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. , 2005, Journal of medicinal chemistry.

[47]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[48]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[49]  M. Santoro,et al.  Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. , 1995, Biochemical and biophysical research communications.

[50]  Daniel K. Treiber,et al.  Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. , 2006, Cancer research.